-
Edirisinghe, HS, Rajapaksa, AE, Royce, SG, Sourial, M, Bischof, RJ, Anderson, J, Sarila, G, Nguyen, CD, Mulholland, K, Ha, LA, et al.
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection.
Viruses
15(11)
:
2276
2024
view publication
-
Batmunkh, T, Moore, KA, Thomson, H, Altangerel, B, Amraa, O, Avaa, N, Batbayar, L, Batsukh, K, Bright, K, Burentogtokh, T, et al.
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.
The Lancet Regional Health - Western Pacific
42:
100953
2024
view publication
-
Assantachai, P, Niyomnaitham, S, Toh, ZQ, Thammasalee, M, Pengsorn, N, Monklang, W, Licciardi, PV, Chokephaibulkit, K.
Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.
Frontiers in Immunology
14:
1302041
2024
view publication
-
Leach, AJ, Wilson, N, Arrowsmith, B, Beissbarth, J, Mulholland, EK, Santosham, M, Torzillo, PJ, McIntyre, P, Smith-Vaughan, H, Skull, SA, et al.
Otitis media at 6-monthly assessments of Australian First Nations children between ages 12–36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
International Journal of Pediatric Otorhinolaryngology
175:
111776
2023
view publication
-
Temple, B, Licciardi, P.
Is it time to reconsider how higher valency pneumococcal conjugate vaccines are evaluated?.
The Lancet Infectious Diseases
2023
view publication